U.S. market Closed. Opens in 1 day 2 hours 9 minutes

SEEL | Seelos Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue2.20MN/AN/AN/A375.00K
Cost of Revenue30.12M53.00KN/AN/A22.56M
Gross Profit-27.91M-53.00KN/AN/A-22.19M
Operating Expenses12.59M70.92M61.67M18.76M29.75M
Selling, General & Admin12.53M12.30M15.02M7.78M7.56M
Research & Development30.12M58.62M46.65M10.98M22.56M
Other Operating ExpensesN/A-3.02M230.00KN/A-375.00K
Operating Income-40.50M-70.92M-61.67M-18.76M-29.75M
Other Expenses / Income2.62M-2.62M-4.38M-342.00K-21.51M
Before Tax Income-37.88M-73.53M-66.05M-19.10M-50.88M
Income Tax ExpensesN/A2.60M1.49M119.00K-497.00K
Net Income-37.88M-76.14M-67.53M-19.22M-50.38M
Interest Expenses75.00K14.00K1.60M164.00K29.00K
Basic Shares Outstanding4.90M3.54M3.03M1.49M676.96K
Diluted Shares Outstanding4.90M3.54M3.03M1.49M676.96K
EBITDA-37.75M-73.47MN/AN/A-29.33M
EBITDA Margin-1,713.57%0.00%0.00%0.00%-7,821.33%
EBIT-37.81M-73.52M-64.45M-18.94M-50.85M
EBIT Margin-1,716.16%0.00%0.00%0.00%-13,560.27%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙